{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:17:53Z","timestamp":1787883473728,"version":"build-2784847793"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Inflammatory breast cancer (IBC) is an aggressive form of cancer for which trimodality therapy (TMT) is standard, but TMT use may be decreasing. Survival outcomes between patients with IBC and non-IBC by tumor subtype are unclear, and survival trends over time have not been reported.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare breast cancer (BC)\u2013specific survival (BCSS) and overall survival (OS) between IBC and non-IBC by tumor subtype, and to examine trends in TMT use and survival over time.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study used population-based data from the Surveillance, Epidemiology, and End Results program. Patients with stage III BC diagnosed between 2010 and 2020 were categorized as having IBC (T4d) and non-IBC. TMT included neoadjuvant systemic therapy, mastectomy, dissection of more than 5 axillary nodes, and adjuvant radiation. Data analysis was conducted from January to October 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Diagnosis of IBC and receipt of TMT.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n BCSS and OS between IBC and non-IBC were evaluated stratified by tumor subtype. Multivariable Cox models were used to estimate adjusted hazard ratios (aHRs) across subtypes and to assess trends in BCSS and OS over time.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 47\u202f702 patients with stage III BC (3227 with IBC [6.8%] and 44\u202f475 with non-IBC [93.2%]), the median (IQR) age at diagnosis was 57 (47-68) years, and 47\u202f215 (99.0%) were women. Across all tumor subtypes, IBC was associated with worse BCSS compared with non-IBC, including hormone receptor\u2013positive, ERBB2\u2013negative disease (aHR, 1.53; 95% CI, 1.37-1.70) and triple-negative BC (aHR, 1.69; 95% CI, 1.50-1.89). Among patients with IBC, TMT receipt was associated with better BCSS compared with no TMT (aHR, 0.67; 95% CI, 0.59-0.77). From 2010 to 2020, use of TMT among patients with IBC decreased from 33.9% (111 of 327 patients) to 24.2% (52 of 215 patients), and no significant improvement in BCSS or OS over time was observed, whereas survival improved among patients with non-IBC.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of stage III BC, IBC was associated with worse BCSS and OS than stage III non-IBC across all tumor subtypes. TMT use in IBC was low and decreased significantly over time. BCSS and OS did not improve over time for patients with IBC treated with TMT, whereas BCSS and OS improved for those with non-IBC.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.5014","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:00:21Z","timestamp":1775746821000},"page":"e265014","source":"Crossref","is-referenced-by-count":2,"title":["Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Jos\u00e9 P.","family":"Leone","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julieta","family":"Leone","sequence":"additional","affiliation":[{"name":"Grupo Oncol\u00f3gico Cooperativo del Sur, Neuqu\u00e9n, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"De Placido","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faina","family":"Nakhlis","sequence":"additional","affiliation":[{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Breast Surgery, Department of Surgery, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Schlam","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly A.","family":"Hirko","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Michigan State University, East Lansing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Hazra","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Preventive Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Troll","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Bellon","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Radiation Oncology, Brigham and Women\u2019s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos T.","family":"Vallejo","sequence":"additional","affiliation":[{"name":"Grupo Oncol\u00f3gico Cooperativo del Sur, Neuqu\u00e9n, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Lynce","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"issue":"6","key":"zoi260185r1","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1200\/JCO.1992.10.6.1014","article-title":"Inflammatory breast cancer: a review.","volume":"10","author":"Jaiyesimi","year":"1992","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi260185r2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10549-021-06434-x","article-title":"Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research.","volume":"192","author":"Jagsi","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"zoi260185r3","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1093\/jnci\/djaf088","article-title":"Development of a multi-institutional dataset to validate a novel inflammatory breast cancer diagnostic score.","volume":"117","author":"Lynce","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"zoi260185r4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10549-020-05938-2","article-title":"Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database.","volume":"185","author":"Abraham","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"zoi260185r5","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1002\/cncr.25682","article-title":"Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study.","volume":"117","author":"Dawood","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"zoi260185r6","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/annonc\/mdt525","article-title":"Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.","volume":"25","author":"Masuda","year":"2014","journal-title":"Ann Oncol"},{"issue":"5","key":"zoi260185r7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024: NCCN Clinical Practice Guidelines in Oncology.","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"19","key":"zoi260185r8","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1200\/JCO.2014.55.1978","article-title":"Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database.","volume":"32","author":"Rueth","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi260185r9","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/annonc\/mdu121","article-title":"Survival of women with inflammatory breast cancer: a large population-based study.","volume":"25","author":"Dawood","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"zoi260185r10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/BF02573060","article-title":"Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer.","volume":"9","author":"Stearns","year":"2002","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"zoi260185r11","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijsu.2009.04.012","article-title":"Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer.","volume":"7","author":"Hidar","year":"2009","journal-title":"Int J Surg"},{"issue":"1","key":"zoi260185r12","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/j.clbc.2017.06.014","article-title":"Prospective feasibility trial of sentinel lymph node biopsy in the setting of inflammatory breast cancer.","volume":"18","author":"DeSnyder","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"zoi260185r13","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1159\/000512202","article-title":"Sentinel lymph node biopsy may prevent unnecessary axillary dissection in patients with inflammatory breast cancer who respond to systemic treatment.","volume":"16","author":"Karanlik","year":"2021","journal-title":"Breast Care (Basel)"},{"issue":"3","key":"zoi260185r16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.surg.2021.08.061","article-title":"Inflammatory breast cancer, trimodal treatment, and mortality: does where you live matter?","volume":"171","author":"Relation","year":"2022","journal-title":"Surgery"},{"issue":"2","key":"zoi260185r17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.54506","article-title":"Trends in guideline-concordant care for inflammatory breast cancer.","volume":"8","author":"Tadros","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"12","key":"zoi260185r18","doi-asserted-by":"publisher","first-page":"8668","DOI":"10.1245\/s10434-025-17585-2","article-title":"Trends in surgical treatment for cT4 breast cancer after neoadjuvant systemic therapy: a nationwide study in The Netherlands.","volume":"32","author":"Jansen","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"zoi260185r19","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.3390\/cancers15092450","article-title":"Conservative surgery in cT4 breast cancer: single-center experience in the neoadjuvant setting.","volume":"15","author":"Franco","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"zoi260185r20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41523-025-00765-4","article-title":"Inflammatory breast cancer, best practice in the community setting.","volume":"11","author":"Takahashi","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"zoi260185r21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"2","key":"zoi260185r22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089778","article-title":"Outcomes of sentinel lymph node dissection alone vs. axillary lymph node dissection in early stage invasive lobular carcinoma: a retrospective study of the surveillance, epidemiology and end results (SEER) database.","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"zoi260185r23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/cncr.23514","article-title":"How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer?","volume":"113","author":"Yi","year":"2008","journal-title":"Cancer"},{"issue":"14","key":"zoi260185r24","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1158\/1078-0432.CCR-24-2081","article-title":"Clinicogenomic characterization of inflammatory breast cancer.","volume":"31","author":"Priedigkeit","year":"2025","journal-title":"Clin Cancer Res"},{"key":"zoi260185r15","volume-title":"AJCC Cancer Staging Manual","author":"Edge","year":"2009","edition":"7th ed"},{"key":"zoi260185r14","unstructured":"National Cancer Institute; Surveillance, Epidemiology, and End Results Program. Overview of the SEER program. Accessed February 23, 2026. https:\/\/seer.cancer.gov\/about\/overview.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2847558\/leone_2026_oi_260185_1775145208.26932.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:00:23Z","timestamp":1775746823000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2847558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.5014","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]}}}